This suggests that, in the neoadjuvant setting, successful immunotherapy may rely more on the pre-existing state of tumor-infiltrating T cells rather than “clonal replacement.” In addition, the expansion of bystander CD8+ T cells may obscure early T cell responses post-ICI treatment. Here, CD8A is linked to neoplasm.